All four analogues exhibited in vivo PSMA tumor-targeting comparable to [18F]DCFPyL with tumor uptakes and T:M ratios, ranging from 27 to 17%ID/g and 203 to 74 T:M, respectively, which were at least 8-fold greater than non-target tissues except for the kidney and liver. The gene discussed is FOLH1; the disease is neoplasm.